Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Melanoma | Research

Single-cell analysis of the cellular landscape of vulvar melanoma provides new insight for immunotherapy administration

Authors: Xinqi Wang, Jiahui Li, Yifei Li, Mingyi Lv, Xue Dong, Zhenxin Fan, Tao Guo

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Background

Vulvar and vaginal melanoma (VuM & VaM) is a rare gynecologic malignancy with high mortality but low effectiveness to checkpoint immunotherapy compared to cutaneous melanoma. This article aims to elucidate the role of the disordered immune microenvironment in cancer progression in VuM.

Methods

At first, this article applied single-cell RNA sequencing (scRNA-seq) to the VuM obtained from a 68-year-old female patient, and constructed a single-cell atlas of VuM consist of 12,243 single cells. Then this article explores the genomic complexity and core signal channel in VuM microenvironment.

Results

This article provides new insights about the pathogenesis of VuM based on single-cell resolution data. It was found that the activation of CD8+ T cell contributed to induce tumor angiogenesis and immune escape, and the activation of the antigen-presenting molecular function participated in melanoma metastasis.

Conclusion

This article provided new insights into underlining VuM molecular regulation and potential signaling involved in immunotherapy, which would benefit the clinical practice and administration.
Appendix
Available only for authorised users
Literature
1.
2.
Wohlmuth C, Wohlmuth-Wieser I, May T, Vicus D, Gien LT, Laframboise S. Malignant melanoma of the Vulva and Vagina: a US Population-based study of 1863 patients. Am J Clin Dermatol. 2020;21(2):285–95.CrossRefPubMed
3.
Gadducci A, Carinelli S, Guerrieri ME, Aletti GD. Melanoma of the lower genital tract: prognostic factors and treatment modalities. Gynecol Oncol. 2018;150(1):180–9.CrossRefPubMed
4.
Ragnarsson-Olding B, Johansson H, Rutqvist LE, Ringborg U. Malignant melanoma of the vulva and vagina. Trends in incidence, age distribution, and long-term survival among 245 consecutive cases in Sweden 1960–1984. Cancer. 1993;71(5):1893–7.CrossRefPubMed
5.
Hou JY, Baptiste C, Hombalegowda RB, Tergas AI, Feldman R, Jones NL, Chatterjee-Paer S, Bus-Kwolfski A, Wright JD, Burke WM. Vulvar and vaginal melanoma: a unique subclass of mucosal melanoma based on a comprehensive molecular analysis of 51 cases compared with 2253 cases of nongynecologic melanoma. Cancer. 2017;123(8):1333–44.CrossRefPubMed
6.
Yu Y, Tse KY, Lee HHY, Chow KL, Tsang HW, Wong RWC, Cheung ETY, Cheuk W, Lee VWK, Chan WK, et al. Predictive biomarkers and tumor microenvironment in female genital melanomas: a multi-institutional study of 55 cases. Mod Pathology: Official J United States Can Acad Pathol Inc. 2020;33(1):138–52.CrossRef
7.
Li L, Xiong F, Wang Y, Zhang S, Gong Z, Li X, He Y, Shi L, Wang F, Liao Q, et al. What are the applications of single-cell RNA sequencing in cancer research: a systematic review. J Experimental Clin cancer Research: CR. 2021;40(1):163.CrossRefPubMedCentral
8.
Haque A, Engel J, Teichmann SA, Lönnberg T. A practical guide to single-cell RNA-sequencing for biomedical research and clinical applications. Genome Med. 2017;9(1):75.CrossRefPubMedPubMedCentral
9.
Liu C, Li X, Huang Q, Zhang M, Lei T, Wang F, Zou W, Huang R, Hu X, Wang C et al. Single-cell RNA-sequencing reveals radiochemotherapy-induced innate immune activation and MHC-II upregulation in cervical cancer. Signal Transduct Target Therapy 2023, 8(1).
10.
Liu C, Zhang M, Yan X, Ni Y, Gong Y, Wang C, Zhang X, Wan L, Yang H, Ge C, et al. Single-cell dissection of cellular and molecular features underlying human cervical squamous cell carcinoma initiation and progression. Sci Adv. 2023;9(4):eadd8977.CrossRefPubMedPubMedCentral
11.
12.
Kanehisa M, Furumichi M, Sato Y, Kawashima M, Ishiguro-Watanabe M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2023;51(D1):D587–d592.CrossRefPubMed
13.
14.
15.
DiLillo DJ, Yanaba K, Tedder TF. B cells are required for optimal CD4 + and CD8 + T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice. J Immunol (Baltimore Md: 1950). 2010;184(7):4006–16.CrossRef
16.
Chi P, Jiang H, Li D, Li J, Wen X, Ding Q, Chen L, Zhang X, Huang J, Ding Y. An immune risk score predicts progression-free survival of melanoma patients in South China receiving anti-PD-1 inhibitor therapy-a retrospective cohort study examining 66 circulating immune cell subsets. Front Immunol. 2022;13:1012673.CrossRefPubMedPubMedCentral
17.
Potrony M, Carreras E, Aranda F, Zimmer L, Puig-Butille JA, Tell-Marti G, Armiger N, Sucker A, Gimenez-Xavier P, Martinez-Florensa M, et al. Inherited functional variants of the lymphocyte receptor CD5 influence melanoma survival. Int J Cancer. 2016;139(6):1297–302.CrossRefPubMedPubMedCentral
18.
Ladányi A. Prognostic and predictive significance of immune cells infiltrating cutaneous melanoma. Pigment cell & Melanoma Research. 2015;28(5):490–500.CrossRef
19.
Allavena P, Sica A, Solinas G, Porta C, Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol/Hematol. 2008;66(1):1–9.CrossRefPubMed
20.
Fregni G, Perier A, Avril MF, Caignard A. NK cells sense tumors, course of disease and treatments: consequences for NK-based therapies. Oncoimmunology. 2012;1(1):38–47.CrossRefPubMedPubMedCentral
21.
Karlen SJ, Miller EB, Wang X, Levine ES, Zawadzki RJ. Burns MEJJon: monocyte infiltration rather than microglia proliferation dominates the early immune response to rapid photoreceptor degeneration. 2018, 15(1):1–16.
22.
Zhou S, Liang Y, Zhang X, Liao L, Yang Y, Ouyang W, Xu HJ. SHARPIN promotes melanoma progression via Rap1 signaling pathway. JoID. 2020;140(2):395–403. e396.
23.
Stoebner PE, Lavabre-Bertrand T, Henry L, Guiraud I, Carillo S, Dandurand M, Joujoux JM, Bureau JP. Meunier LJBJoD: high plasma proteasome levels are detected in patients with metastatic malignant melanoma. 2005, 152(5):948–53.
24.
Jiang S, Li M, Hu Y, Zhang Z, Lv H. Multifunctional self-assembled micelles of galactosamine-hyaluronic acid-vitamin E succinate for targeting delivery of norcantharidin to hepatic carcinoma. Carbohydr Polym. 2018;197:194–203.CrossRefPubMed
25.
Hu C, Ni Z, Li BS, Yong X, Yang X, Zhang JW, Zhang D, Qin Y, Jie MM, Dong H, et al. hTERT promotes the invasion of gastric cancer cells by enhancing FOXO3a ubiquitination and subsequent ITGB1 upregulation. Gut. 2017;66(1):31–42.CrossRefPubMed
26.
Cheng N, Brantley D, Fang WB, Liu H, Fanslow W, Cerretti DP, Bussell KN, Reith A, Jackson D, Chen J. Inhibition of VEGF-dependent multistage carcinogenesis by soluble EphA receptors. Neoplasia. 2003;5(5):445–56.CrossRefPubMedPubMedCentral
27.
Gauthier T, Uzan C, Gouy S, Kane A, Calvacanti A, Mateus C, Robert C, Kolb F, Morice P. [Malignant melanoma of the vagina: pejorative location]. Gynecologie Obstetrique & Fertilite. 2012;40(5):273–8.CrossRef
28.
Göbel J, Košťál M, Hensel G, Hátlová J. Primary malignant melanoma of the vagina, case report and review of the literature. Ceska Gynekol. 2018;83(3):201–199.PubMed
29.
Vaysse C, Pautier P, Filleron T, Maisongrosse V, Rodier JF, Lavoue V, Reyal F, Thomas L, de la Fouchardière A, Delannes M. A large retrospective multicenter study of vaginal melanomas: implications for new management. Melanoma Res. 2013;23(2):138–46.CrossRefPubMed
30.
To C, Farnsworth RH, Vail ME, Chheang C, Gargett CE, Murone C, Llerena C, Major AT, Scott AM, Janes PW, et al. Hypoxia-controlled EphA3 marks a human endometrium-derived multipotent mesenchymal stromal cell that supports vascular growth. PLoS ONE. 2014;9(11):e112106.CrossRefPubMedPubMedCentral
31.
Balakrishnan A, Bleeker FE, Lamba S, Rodolfo M, Daniotti M, Scarpa A, van Tilborg AA, Leenstra S, Zanon C, Bardelli A. Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma. Cancer Res. 2007;67(8):3545–50.CrossRefPubMed
32.
Lawrenson ID, Wimmer-Kleikamp SH, Lock P, Schoenwaelder SM, Down M, Boyd AW, Alewood PF, Lackmann M. Ephrin-A5 induces rounding, blebbing and de-adhesion of EphA3-expressing 293T and melanoma cells by CrkII and rho-mediated signalling. J Cell Sci. 2002;115(Pt 5):1059–72.CrossRefPubMed
33.
Kuijper S, Turner CJ, Adams RH. Regulation of angiogenesis by eph-ephrin interactions. Trends Cardiovasc Med. 2007;17(5):145–51.CrossRefPubMed
34.
Jungwirth U, van Weverwijk A, Evans RJ, Jenkins L, Vicente D, Alexander J, Gao Q, Haider S, Iravani M, Isacke CM. Impairment of a distinct cancer-associated fibroblast population limits tumour growth and metastasis. Nat Commun. 2021;12(1):3516.CrossRefPubMedPubMedCentral
35.
Buechler MB, Pradhan RN, Krishnamurty AT, Cox C, Calviello AK, Wang AW, Yang YA, Tam L, Caothien R, Roose-Girma M, et al. Cross-tissue organization of the fibroblast lineage. Nature. 2021;593(7860):575–9.CrossRefPubMed
36.
Luo H, Tu G, Liu Z, Liu M. Cancer-associated fibroblasts: a multifaceted driver of breast cancer progression. Cancer Lett. 2015;361(2):155–63.CrossRefPubMed
37.
Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discovery. 2019;18(2):99–115.CrossRefPubMed
38.
Koopmans T, Rinkevich Y. Mesothelial to mesenchyme transition as a major developmental and pathological player in trunk organs and their cavities. Commun Biology. 2018;1:170.CrossRef
39.
Aslam MI, Abraham J, Mansoor A, Druker BJ, Tyner JW, Keller C. PDGFRβ reverses EphB4 signaling in alveolar rhabdomyosarcoma. Proc Natl Acad Sci USA. 2014;111(17):6383–8.CrossRefPubMedPubMedCentral
40.
Hadjimichael AC, Pergaris A, Kaspiris A, Foukas AF, Kokkali S, Tsourouflis G, Theocharis S. The EPH/Ephrin System in Bone and Soft Tissue Sarcomas’ Pathogenesis and Therapy: New Advancements and a Literature Review. Int J Mol Sci 2022, 23(9).
41.
Girard CA, Lecacheur M, Ben Jouira R, Berestjuk I, Diazzi S, Prod’homme V, Mallavialle A, Larbret F, Gesson M, Schaub S, et al. A feed-Forward Mechanosignaling Loop confers resistance to therapies targeting the MAPK pathway in BRAF-Mutant Melanoma. Cancer Res. 2020;80(10):1927–41.CrossRefPubMed
42.
Tirosh I, Izar B, Prakadan SM, Wadsworth MH 2nd, Treacy D, Trombetta JJ, Rotem A, Rodman C, Lian C, Murphy G, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Sci (New York NY). 2016;352(6282):189–96.
43.
Gong L, Kwong DL, Dai W, Wu P, Li S, Yan Q, Zhang Y, Zhang B, Fang X, Liu L, et al. Comprehensive single-cell sequencing reveals the stromal dynamics and tumor-specific characteristics in the microenvironment of nasopharyngeal carcinoma. Nat Commun. 2021;12(1):1540.CrossRefPubMedPubMedCentral
Metadata
Title
Single-cell analysis of the cellular landscape of vulvar melanoma provides new insight for immunotherapy administration
Authors
Xinqi Wang
Jiahui Li
Yifei Li
Mingyi Lv
Xue Dong
Zhenxin Fan
Tao Guo
Publication date
01-12-2024
Publisher
BioMed Central
Keywords
Melanoma
Melanoma
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-11839-0

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue

Research

Methylation-regulated tumor suppressor gene PDE7B promotes HCC invasion and metastasis through the PI3K/AKT signaling pathway

Research

Radiogenomic analysis of ultrasound phenotypic features coupled to proteomes predicts metastatic risk in primary prostate cancer

Research

Dietary supplement intake in women with breast cancer before and after diagnosis: results from the SUCCESS C trial

Research

Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer

Research

Comprehensive machine learning-based preoperative blood features predict the prognosis for ovarian cancer

Research

A nomogram based on nutritional and inflammatory parameters to predict DMFS and identify beneficiaries of adjuvant chemotherapy in IVA-stage nasopharyngeal carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits